WALTHAM, Mass.--Genome Therapeutics here has released version 2.0 of PathoGenome, the company's proprietary microbial sequence database. The new version uses a more powerful and efficient bioinformatics platform and features highly finished genomic sequence information for more than a dozen pathogens, according to the company.
The upgraded PathoGenome is currently being installed at the research facilities of the database's subscribers, who include Bayer, Bristol-Myers Squibb, and Schering-Plough. The original version was introduced in May. "The feedback we've received from our customers has been excellent, with reports of new potential antiinfective targets already identified. This rapid success underscores the power of comparative genomics to define targets that are common to multiple organisms," commented Robert Hennessey, Genome Therapeutics' chairman, president, and CEO.